Gonorrhea and Chlamydia

We talked about most STIs in a series back at the beginning of 2019! This podcast is an update to the treatment guidelines and will replace our last episode on gonorrhea and chlamydia, as these two bugs had some changes in treatment with the 2021 CDC STI guidelines.

First of all, why are we doing these two STDs together? 

  • Because they have a lot of common symptomatology 

  • They may come together (ie. if you have one, you may have the other) 

  • We usually order the two tests together (say it in one breath anyway in the clinic or the ED) 

What are gonorrhea and chlamydia and why do we care? 

  • Both are sexually transmitted infections that anyone can get if they are sexually active (any kind of sex), and there is vertical transmission between mother and child 

  • Gonorrhea 

    • Caused by bacteria Neisseria gonorrhoeae (gram negative diplococci) 

    • 1.6 million new infections annually in the US

      • More than 50% occur in patients aged 15-24

    • Usually symptomless but in men can cause burning with urination, penile discharge, or even testicular pain 

    • In women, 50% are symptomless but can lead to burning with urination, vaginal discharge, intermenstrual bleeding/postcoital spotting, pelvic pain

    • Can also affect other areas like throat or anus 

    • If untreated, it can lead to pelvic inflammatory disease and infertility. Additionally, at risk for disseminated gonococcal infection 

      • Skin pustules/petechiae, septic arthritis, meningitis, endocarditis 

      • Very rare (0.6-3% of infected women and 0.4-0.7% of infected men 

      • In pregnant patients: septic abortion, chorio, neonatal blindness 

  • Chlamydia 

    • Caused by bacteria Chlamydia trachomatis (gram negative bacteria that only replicates in host cells).

    • 4 million new infections annually in the US

      • More than 65% occur in patients aged 15-24

      • Some estimates show at any given time, 1 in 20 sexually active women aged 15-24 has active chlamydia infection in the US.

    • Again, usually symptomless (70-80%), but can cause vaginal discharge and burning with urination in women 

    • In men, can have discharge from penis, burning with urination, pain and swelling in testicles. 

    • Rectal, oral/throat infections are also possible.

    • If untreated, can also cause PID and infertility in women → around 15% of women will develop.

    • Also can cause chlamydia conjunctivitis or trachoma → blindness 

    • Reactive arthritis → can’t see, can’t pee, can’t climb a tree = arthritis, conjunctivitis, urethral inflammation 

How do we diagnose them? 

  • Usually a urine test, but can also do endocervical swab, vaginal swab, rectal swab, or pharyngeal swab 

    • Nucleic acid amplification test = gold standard 

  • Who should be tested? 

    • CDC recommends screening:

      • Of anyone with concern for symptoms;

      • Annually for GC/chlamydia for all sexually active women younger than 25 years 

      • Opportunistic screening for older women with identified risk factors (ie. new or multiple sexual partners or sex partner who recently had an STI) 

    • For men: once a year for GC/chlamydia for all sexually active MSM, and more frequently (q3-6 months) for MSM who have HIV or if they have multiple or anonymous partners 

How do we treat gonorrhea and chlamydia? - note, this is only for adolescents and adults 

  • Treating gonorrhea (NOT disseminated) 

    • Gonorrhea is becoming more and more resistant to antibiotics, and we are down to one class of antibiotic that really treats it: cephalosporins 

    • CDC recommends: ceftriaxone 500mg IM x1

      • This is an update to the previous recommendations, which used 250mg. This reflects the changing state of antibiotic resistance of gonorrhea.

      • Test of cure is recommended for throat infections and for pregnant patients, but not necessarily for genital or rectal infections.

    • If cephalosporin allergic:

      • Gentamicin 240mg IM in single dose, AND Azithromycin 2g orally in single dose.

  • Treating chlamydia 

    • Recommended regimen by the CDC: Doxycycline 100mg PO twice daily for 7 days.

      • Alternative regimens include:

        • Azithromycin 2g orally, single dose

        • Levofloxacin 500 mg orally for 7 days 

    • Azithromycin has lower efficacy amongst persons with concomitant rectal infection, which is why the doxycycline regimen is preferred.

      • Repeat screening may be needed to ensure efficacy of the single-dose azithro regimen.

  • Expedited partner treatment - treat the sexual partner of the patient diagnosed with chlamydia or gonorrhea without first examining the sexual partner 

    • CDC says: EPT is a useful option to facilitate partner management in states where it is permissible, and reduces re-infection risk for the patient while treating the partner.

    • Should always counsel the patient that partner and patient should refrain from having intercourse for at least 7 days after all partners have been treated.

GC/chlamydia in pregnancy 

  • Screen in first trimester and if positive, should be treated

    • Exception: for chlamydia, Azithromycin 1g orally x1 is the recommended regimen.

    • These medications are safe during pregnancy, and risks outweigh the benefits of not treating

    • Expedited partner treatment is recommended where permissible.

    • Test of cure is recommended in three weeks (and should also screen in 3rd trimester again)

  • Pregnancy-specific risks of non-treatment

    • Vertical transmission to newborn 

    • Chlamydia: conjunctivitis (5-14 days after birth), and pneumonia (4-12 weeks of age) 

    • Gonorrhea: conjunctivitis (more purulent compared to watery discharge of chlamydia… both can lead to blindness!) 

      • Gentamicin/erythomycin eye gel helps to prevent these and why we use it!

    • Otherwise: septic abortions, intact chorio, etc. 

A final “fun fact” we had dug out in the original GC/CT episode…

  • There is no consensus as to why gonorrhea is called the clap… but some theories: 

    • Old English word “clappan” means throbbing or beating -- could mean the burning during urination with gonorrhea 

    • Proposed treatment during medieval times of “clapping” the penis or slamming the penis between both hands on a hard surface to get rid of the discharge/pus 






HIV in the Non-Pregnant Patient

We jump back to our STI saga to cover HIV today. ACOG PB 167 and CO 596 make for supplementary reading for this show.

The CDC and USPSTF recommend at least one-time HIV screening in most women. The CDC goes further to recommend up to annual screening in certain high-risk groups, including IV drug users, > 1 sex partner annually or known sex partner with HIV, those who exchange sex for money or goods, and MSM.

Screening is important, because almost 25% of new cases occur in women, and heterosexual intimate contact is the most common form of disease spreading. ACOG subscribes to a philosophy of “opt out” testing, by which HIV screening should be considered routine, with the patient able to opt out. Physicians need to document the reason for this in their notes. Screening tests are broken into rapid and confirmatory. A positive rapid screen should always be followed with a confirmatory test, as the rapid screens have high sensitivity, but lower specificity.

GYN care may vary somewhat with positive HIV status. For Pap smears, PB 167 describes an appropriate algorithm for dealing with initial screening and some positive results:

ACOG PB 167

ACOG PB 167

We spend some time reviewing the treatment of other STIs in the podcast briefly, all of which are reviewed in PB 167 as well. Highlights include:

  • Using 1 week rather than single-dose metronidazole treatment for trichomonal infections

  • Re-testing any positive GC/CT testing result at 3 months, due to high risk of re-infection

  • Screening for most STIs at entry to care for HIV-affected patients.

Birth control is also another important topic for HIV-affected patients. ACOG and the CDC recommend use of dual-contraception — that is, a barrier method and a hormonal method — to prevent viral spread. Certain forms of hormonal contraception may be affected by antiretroviral drugs:

  • CHCs: The NNRTI non nucleoside reverse transcriptase inhibitor efavirenz and certain protease inhibitors (-navir) may decrease efficacy of combined methods by reducing contraceptive hormone levels; however, they are considered US MEC Category 2.

    • The exception to this rule is fosamprenavir, as CHCs also lead to decreased levels of this protease inhibitor (US MEC 3).

  • Etonogestrel implant:  Similarly to CHCs, there are theoretical risks in decreased contraceptive effectiveness for patients on efavirenz; however, the implant remains US MEC 2.

  • DMPA: MEC category 1 for all users, except for those on fosamprenavir; there is limited evidence DMPA decreases fosamprenavir levels like CHCs (US MEC 2).

  • IUDs: MEC category 1 for all users!

  • Emergency contraception: for oral medicatons such as levenorgestrel and ulipristal, these should be offered to HIV-affected women as the benefits of emergency contraception are considered to outweigh the risks in this group. Similarly to CHCs, there is theoretical risk of decreased efficacy of these methods among women taking efavirenz.

Finally, in a preview to our next episode, we talk about preconception counseling for HIV-affected patients. The goal for any patient with HIV is to achieve a negative viral load, and for OB-GYNs, this is important to limit vertical transmission. Efavirenz has been associated with neural tube defects, so should be avoided in pregnancy if possible.

Conceiving is safest through artificial insemination. However, if natural conception is desired. OB-GYNs should discuss limiting unprotected intercourse to ovulatory times, and using pre-exposure prophylaxis for the patient, or her partner, in serodiscordant couples. This generally involves a daily regimen of tenofovir/emtricitabine (Truvada) for 1 month prior to, and 1 month after, conception. Risk reduction is estimated to be somewhere between 63-75%, and the best-available data suggests this is likely safe.